Cosmos Health Inc. reports developments across a vertically integrated healthcare platform that includes wholesale pharmaceutical distribution, contract manufacturing, proprietary nutraceutical brands and research and development. Recurring updates cover U.S. commercialization of the 18 Series nutraceutical portfolio, including Noor18, Liv18, Cur18 and Fort18, as well as Sky Premium Life orders, international distribution relationships and product launches.
Company news also covers financial results, margin and revenue drivers at Cana Laboratories, CosmoFarm and Decahedron, AI investments including the Cloudscreen drug-repurposing platform, and Nasdaq listing-compliance or governance matters tied to its common stock.
Cosmos Health (NASDAQ:COSM) reported record Q1 2026 revenue of $17.93M, up 30.7% from $13.71M in Q1 2025, with adjusted revenue of $18.40M. Gross profit was $1.38M and adjusted gross profit $1.85M. Net loss widened to $2.81M, while adjusted EBITDA was near breakeven at -$0.23M.
Total liabilities fell 9.6% to $42.54M, stockholders' equity rose 7.6% to $19.83M, and liquid assets totaled $4.3M, including $2.2M cash. Management noted record momentum continuing into Q2 2026 and highlighted active U.S. nutraceuticals expansion.
Cosmos Health (NASDAQ:COSM), via subsidiary Cana Laboratories, entered an advisory agreement with the European Investment Bank (EIB) to advance a potential EIB-backed R&D financing program.
The EIB Venture Debt scheme could fund up to €25M, or 50% of Cosmos Health's planned €50M R&D program, subject to milestones and no assurance of completion.
Potential funding is aimed at accelerating the Company's AI-powered R&D pipeline across weight management, oncology, multiple sclerosis, gliomas, hematologic malignancies, and allergic inflammation.
Cosmos Health (NASDAQ:COSM) has requested withdrawal of its Registration Statement on Form S-1 (File No. 333-283910) with the SEC. The S-1, originally filed December 18, 2024 and last amended June 3, 2025, covered a planned public offering the company no longer intends to pursue at this time.
The Registration Statement was never declared effective, and no securities were sold in connection with the proposed offering. The company notes this announcement is not an offer or solicitation to buy or sell securities.
Cosmos Health (NASDAQ:COSM) projects its new nutraceutical Fort18™ will generate over $3.2 million in incremental annual U.S. revenue within 12–18 months, based on current commercialization plans and internal assumptions.
Fort18™, targeting men's sexual stamina and endurance, is expected to launch in June 2026 via a staged rollout starting with e-commerce.
Cosmos Health (NASDAQ:COSM) announced the U.S. launch of Fort18™, a men's sexual stamina supplement joining its 18 Series on May 6, 2026. Fort18™ uses a proprietary five-ingredient botanical blend standardized to ≥20% saponins and 1.5% flavonoids and is dosed at 500mg twice daily.
Published clinical research (randomized, double-blind, placebo-controlled; n=60) reported a 5.1-fold improvement in endurance versus placebo over eight weeks, with onset by Week 4. IP for the blend's standardization fingerprint is held by the ingredient supplier.
Cosmos Health (NASDAQ:COSM) projects Cur18™ will generate over $2.5 million in incremental annual U.S. revenue within 12–18 months based on its current commercialization strategy and internal assumptions. Cur18™ is a curcumin-based nutraceutical in the company’s 18 Series, planned initially for DTC e-commerce with potential retail expansion.
The projection depends on execution of pricing, sales volumes, and distribution expansion.
Cosmos Health (NASDAQ:COSM) launched the 18 Series in the U.S. on April 21, 2026: a science-first nutraceutical platform requiring a patented ingredient, peer-reviewed clinical evidence, and the exact clinical dose.
Three products—Noor18, Liv18, Cur18—target a combined $7.8B U.S. addressable market, cite published RCTs (7+ studies), and use patented actives to build a compounding portfolio aiming for 18 clinically validated products.
Cosmos Health (NASDAQ:COSM) completed Phase 1 for Liv18, finalizing product development, packaging, and initial commercial setup ahead of schedule. U.S. production begins April 2026 at GMP-certified, FDA-registered, UL-audited facilities to reduce tariff exposure and improve supply chain efficiency.
The company projects over $5M in annual revenue for Liv18 at approximately 75% gross margins, driven by a direct-to-consumer model and targeted advertising; early U.S. traction from other products informs commercial expectations.
Cosmos Health (NASDAQ:COSM) will launch Cur18 in the U.S. in Q2 2026, a patented, turmeric‑derived curcumin supplement standardized to ~50% curcuminoids and derived ~98.5% from turmeric.
Published pharmacokinetic research reports up to 39× higher free curcumin bioavailability and 49.5× higher AUC versus standard 95% extracts.
Cosmos Health (NASDAQ:COSM) announced expanded integration of artificial intelligence across operations on April 16, 2026, targeting efficiency, cost reduction, improved customer experience, and sales growth. In certain areas, AI may reduce specific operating expenses by up to 30%, depending on process and automation level.
The company is deploying AI across front-end order and customer management, back-end warehouse, inventory and supply chain, and its proprietary Cloudscreen platform for drug repurposing, supporting both operational gains and R&D efforts.